HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ruptured intracranial dissecting aneurysms: management considerations with a focus on surgical and endovascular techniques to preserve arterial continuity.

AbstractBACKGROUND:
The present retrospective analysis was undertaken to review an institutional experience with 13 intracranial dissecting aneurysms as source of subarachnoid haemorrhage (SAH) among a total of 585 ruptured intracranial aneurysms.
METHODS AND RESULTS:
In 6 patients the vertebral artery (VA) was affected, in 2 patients the basilar artery (BA), in 3 the internal carotid (ICA), in 1 the middle cerebral (MCA) and in 1 the postcommunicating (A2) segment of the anterior cerebral artery (ACA). Maintaining arterial patency was aimed at in all patients. Tangential clipping or circumferential wrapping were used as surgical methods. Endovascular stenting and/or coiling was applied in 2 instances. Four of the 6 VA dissecting aneurysms underwent surgical exploration between 1 and 22 days after haemorrhage. Two patients were in WFNS grade V and died subsequently with the aneurysms untreated, one after rehaemorrhage. In the patients with secured VA aneurysms the postoperative course was uncomplicated with the exception of additional caudal cranial nerve injury in 1 instance. Both BA aneurysms were initially treated by endovascular methods. In the first patient incomplete packing with Gugliemi detachable (GDC) coils was achieved. Follow-up angiography 6 months later showed growth and coil compaction and subsequent wrapping with Teflon fibres resulting in angiographic stabilization. The other BA aneurysm was treated by a combination of a coronary stent and GDC coils. The 3 dissecting ICA aneurysms were all explored surgically. In only 1 instance ICA continuity could be preserved by wrapping, in the other 2 cases a major portion of the vessel wall disintegrated upon removal of the surrounding clot. The only ACA dissecting aneurysm, on A2, was successfully treated with a Dacron cuff. In the single patient with a MCA aneurysm, a decision for conservative management was taken, because neither a surgical nor an endovascular solution was seen as a possibility that did not risk occlusion of lenticulostriate branches. The patient suffered a fatal rehaemorrhage 4 weeks later at her home.
CONCLUSIONS:
The reported experience suggests that in Western countries also dissecting aneurysms are an occasional source of SAH. The outcome in our conservatively managed patients confirms the poor prognosis of conservative management. Wrapping and endovascular stent based methods can achieve stabilization of the dissected artery without sacrificing the artery. Results of treatment appear to depend largely on the location of the dissecting aneurysm.
AuthorsE Uhl, R Schmid-Elsaesser, H-J Steiger
JournalActa neurochirurgica (Acta Neurochir (Wien)) Vol. 145 Issue 12 Pg. 1073-83; discussion 1083-4 (Dec 2003) ISSN: 0001-6268 [Print] Austria
PMID14663564 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Polyethylene Terephthalates
  • Polytetrafluoroethylene
Topics
  • Aged
  • Aortic Dissection (diagnostic imaging, mortality, surgery)
  • Aneurysm, Ruptured (diagnostic imaging, mortality, surgery)
  • Angiography, Digital Subtraction
  • Cerebral Angiography
  • Disability Evaluation
  • Dominance, Cerebral (physiology)
  • Embolization, Therapeutic
  • Female
  • Follow-Up Studies
  • Glasgow Outcome Scale
  • Humans
  • Intracranial Aneurysm (diagnostic imaging, mortality, surgery)
  • Male
  • Middle Aged
  • Outcome and Process Assessment, Health Care
  • Polyethylene Terephthalates
  • Polytetrafluoroethylene
  • Recurrence
  • Subarachnoid Hemorrhage (diagnostic imaging, mortality, surgery)
  • Surgical Instruments
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: